Compare AbCellera Biologics Inc (ABCL) vs F5 Inc (FFIV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs F5 Inc — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while F5 Inc trades at $417.97 (market cap $23.53B). The key difference: F5 Inc is far larger — about 10× AbCellera Biologics Inc's market cap, and F5 Inc is trading nearer its 52-week high, AbCellera Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | FFIV | |
|---|---|---|
Market Cap | $2.35B | $23.53B |
Sector | Health | Technology |
52-Week High | $8.12 | $424.18 |
52-Week Low | $2.78 | $223.99 |
Enterprise Value | $1.99B | $22.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
F5 (FFIV) trades at $417.11, up 2.16% on the day, reflecting strong momentum after three consecutive quarterly earnings beats. The stock is technically bullish, trading above key support levels, while fundamentals show robust revenue growth to $3.09B in 2025 and a high net income margin of 21.96%. Recent strategic moves include expanding AI security offerings through acquisitions and partnerships, positioning the company in the high-growth cybersecurity sector.
The outlook remains positive given consistent earnings outperformance and strategic focus on AI security, though valuation multiples like a P/E of 34.42 suggest premium pricing. Risks include competitive pressures and execution challenges in integrating new technologies. Analyst consensus is mixed with a $397 price target slightly below current levels, indicating cautious optimism amid growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →
